What's trending

5 most popular innovation stories in Houston this week

A top story this week was Station Houston launching a partnership with Houston universities to combine forces for a summer program. Natalie Harms/InnovationMap

This week's top news includes a few stories highlighting the people behind innovation — from overheard at OTC to a Q&A with a private equity CEO. Plus, Station Houston launches a new program combining forces with Houston universities.

Need more than just trending news on Fridays? Subscribe to our daily newsletter that sends fresh stories straight to your inboxes every morning.

Overheard: Here's the future of oil and gas tech, according to this panel at OTC

Three young professionals took the stage to discuss the future tech of offshore operations in oil and gas. Courtesy photos

The oil and gas industry has a reputation for being a slow adapter when it comes to technology advances, but that's changing — as is the workforce. In the next few years, half of the United States workforce will be millennials, according to the Bureau of Labor Statistics. Continue reading the story.

Finding lab space for startups and independent researchers in Houston needs to be easier, according to this expert

Rentable lab space is hard to come by. Getty Images

Finding coworking space is getting easier and easier for startups, but the same can't be said for startups looking for lab space. If Houston wants to continue to grow and develop its innovation ecosystem — specifically within research and development in the health sciences industry — the city needs more opportunities for small lab space real estate. Continue reading the story.

Station Houston partners with universities to launch new accelerator program

This summer, Station Houston is connecting the dots for student and alumni entrepreneurs within Houston's innovation ecosystem. Station Houston/Facebook

Houston universities — namely the University of Houston and Rice University — have been providing student and alumni entrepreneurs with acceleration programming for some time now through RED Labs and OwlSpark, respectively. But nonprofit acceleration hub Station Houston is connecting the dots with these programs — and inviting more schools to join in — through a new summer acceleration program.

"One of the things we haven't historically had in Houston that other cities have are broad collaborations between our universities to help build on one another's resources and really demonstrate for our young people — the talent that we want to keep here — exactly how deep and strong the opportunity to be in Houston is," Gabriella Rowe, CEO of Station, tells InnovationMap.Continue reading the story.

Private equity executive talks diversifying and Houston's investment ecosystem

Taseer Badar is in the business of making money. Courtesy of ZT Corporate

It's Taseer Badar's job to keep 1,000 investors happy. As CEO and founder of ZT Corporate, that's just a day in the life for him.

Badar has been in the business for over 20 years, and before that, he was on Wall Street as a financial adviser for Morgan Stanley. He realized the dollar went further in his hometown of Houston, so he came back. He started advising on business plans for people he knew, and earned a lot of loyalty from these early entrepreneurs, and grew ZT from there. He found his way into health care, which made up a good majority of his holdings, until about four years ago when he diversified his company and got into the automotive industry. Continue reading the story.

3 Houston innovators to know this week

From rethinking dry cleaning or marketing to flipping the script on pop culture events, here's who to know this week in Houston innovation. Courtesy Photos

This week's batch of Houston innovators to know are all rethinking the way things are being done, from dry cleaning and marketing to pop culture events. Continue reading the story.


Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News